Under the collaboration, Amylin will apply its proprietary screening technologies to evaluate the therapeutic potential of the peptides from Xenome’s proprietary bioactive peptide library derived from natural sources. Amylin will have the right to select and exclusively license lead candidates resulting from a screening program in metabolic and musculoskeletal disease for further development and commercialization, in exchange for milestone payments and royalties payable to Xenome.
In addition to the joint research collaboration agreement, Amylin has made an equity investment in Xenome matched by investments from Queensland BioCapital Funds and Innovis Australia.
Michael Hanley, vice president of discovery research at Amylin, said: “This mutually beneficial collaboration combines Xenome’s proprietary peptide library with Amylin’s therapeutic expertise and creates valuable opportunities to discover and develop novel therapeutics.”